Full-Time

Senior Clinical Scientist

Clinical Development

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$150k - $190kAnnually

Mid, Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • BS/BA or master’s degree in a scientific discipline, or other relevant advanced degree in a health science field.
  • Minimum 4 years of experience in the pharmaceutical or biotechnology industry as a clinical scientist or related role.
  • Oncology experience is preferred.
  • Proficient with software tools (Microsoft Office), Electronic Data Capture, and other custom web-based software.
  • Excellent written and verbal communication skills.
Responsibilities
  • Contribute to clinical development strategy and execution of the Clinical Development Plan (CDP) with a focus on early-phase development.
  • Partner with cross-functional teams with oversight from senior team members to conduct clinical studies, including study start up, execution and close out activities, data review/analysis, and preparation of study reports.
  • Contribute to the development of program-level documents, including but not limited to clinical protocols, investigator’s brochure, clinical study reports, abstracts and manuscripts, presentations, and various other internal and external documents and communications as needed.
  • Conduct ongoing data reviews; prepare and present summaries to internal and external stakeholders.
  • Ensure trial implementation according to the protocol and analyze information to assess issues relating to protocol conduct and/or individual subject safety.
  • Interact with internal and external stakeholders (investigators, study sites, vendors, committees, etc.) in support of clinical trial objectives; responds to or triages questions for appropriate escalation.
  • Conduct literature reviews as needed.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased demand for targeted cancer therapies aligns with their RAS-focused treatments.
  • AI and machine learning trends offer potential to optimize drug development processes.

What critics are saying

  • EQRx acquisition may pose integration challenges affecting operational efficiency.
  • $600M public stock offering could lead to shareholder dilution and affect stock price.
  • Focus on RAS-addicted cancers limits market scope and exposes to competitive risks.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • They focus on RAS-addicted cancers, a niche but significant oncology market.

Help us improve and share your feedback! Did you find this helpful?